INTRODUCTION AND OBJECTIVES:
Olaparib is reported to have antitumor effects for castration-resistant prostate cancer patients with germline mutations in DNA repair genes. Our microarray data showed that simvastatin downregulated DNA repair genes in androgen independent prostate cancer PC-3 cells. In this study, we investigated the combination therapy with Olaparib and simvastatin for castration-resistant and taxane-resistant prostate cancer.
METHODS: Androgen independent PC-3, 22Rv1 and androgen dependent LNCaP human prostate cancer cell lines and PrSC human non-transformed prostate cell were used. We have developed androgen-independent LNCaP cells (LNCaP-LA) by making a trade of FBS for charcoal stripped-FBS gradually. Microarray analyses were performed, followed by Ingenuity Pathway Analysis. mRNA and protein expressions were evaluated by quantitative real-time PCR and Western blot analysis, respectively. To knockdown a candidate gene, cells were transfected with siRNA. Cell viability was determined by MTS assay and cell counts.
RESULTS: Simvastatin altered many gene expressions in PC-3 cells. Microarray data and Ingenuity Pathway Analysis showed that the number of differentially expressed genes was the biggest in the pathway of "Role of BRCA1 in DNA Damage Response" (Fig.1) . In the validation, mRNA levels of BRCA1, BRCA2, RAD51, BARD1, FANCD2, RFC3, RFC4, RFC5, MRE11A, FANCA and FANCG, which were listed in "Role of BRCA1 in DNA Damage Response", were decreased significantly by simvastatin in PC-3 cells. Simvastatin decreased the expressions of BRCA1, FANCD2, RFC3, MRE11A and FANCG in 22Rv1 cells, BRCA2, RAD51, BARD1, RFC3 and RFC5 in LNCaP-LA cells, respectively. On the other hand, the expressions of all these genes were not changed in androgen dependent LNCaP cells after treatment of simvastatin. Moreover, simvastatin increased the expressions of all these genes in PrSC. The reduction in BRCA1 and BRCA2 expressions following siRNA transfection increased cytocidal effects of Olaparib in PC-3 and LNCaP-LA cells. The combination of Olaparib and simvastatin further enhanced the inhibition of cell proliferation compared with treatment with either drug alone in PC-3, 22Rv1 and LNCaP-LA, but not in PrSC. Moreover, we developed 22Rv1 having acquired resistance to Cabazitaxel (22Rv1-CR). In 22Rv1-CR cells, simvastatin also decreased the expressions of BRCA1, BRCA2 and FANCA, and the combination of Olaparib and simvastatin further enhanced the inhibition of cell proliferation compared with treatment with either drug alone.
CONCLUSIONS: Simvastatin alters the expressions of many genes concerned with DNA repair in castration-resistant and taxaneresistant prostate cancer cells. The combination of PARP inhibitor and the drugs, which decrease the expressions of DNA repair genes, can potentially affect castration-resistant and taxane-resistant prostate cancer growth.
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MP81-10 LUTEOLIN SUPPRESSES ANDROGEN RECEPTOR SPLICE VARIANT 7 EXPRESSION VIA MIRNA RECRUITMENT IN CASTRATION-RESISTANT PROSTATE CANCER
Taku Naiki*, Aya Naiki-Ito, Toshiki Etani, Keitaro Iida, Ryosuke Ando, Takashi Nagai, Noriyasu Kawai, Satoru Takahashi, Takahiro Yasui, Nagoya, Japan INTRODUCTION AND OBJECTIVES: There is a need for seeking effective treatments for castration-resistant prostate cancer (CRPC), because its emergence following androgen deprivation therapy is a major clinical problem. In the present study, we investigated chemopreventive and chemotherapeutic potential of luteolin, which is a flavonoid, on prostate cancer including CRPC.
METHODS: Firstly, six-week-old male transgenic rats for adenocarcinoma of prostate (TRAP) were divided into three groups (n [ 12 in each group) and fed the following for 8 weeks: basal diet, diet containing 20 ppm luteolin, and diet containing 100 ppm luteolin. Next, we also focused on androgen receptor splice variant 7 (AR-V7), which contributes to cell proliferation and therapeutic resistance of CRPC, and microarray analysis identified miR-8080, which contains a possible target sequence for AR-V7 3'UTR, as an up-regulated gene following luteolin treatment. Subsequently, in vitro analysis using iRNA and overexpression system as to miR-8080 was established, and the effect of luteolin on cell proliferation and apoptosis in PCai1 and 22Rv1 cells was analyzed. Thirdly, PCai and 22Rv1 cells were subcutaneously implanted in castrated and non-castrated nude mice, and in vivo tumor growth after luteolin and enzalutamide treatment was analyzed.
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